Chronic Lymphocytic Leukemia | Specialty

Dr. Kambhampati on Frontline Ibrutinib Plus Obinutuzumab in CLL

February 6th 2019

Suman Kambhampati, MD, co-medical director, Blood Cancer Program, Sarah Cannon Research Institute, discusses the combination of frontline ibrutinib plus obinutuzumab for the treatment of patients with chronic lymphocytic leukemia.

FDA Approves Ibrutinib Plus Obinutuzumab in Frontline CLL/SLL

January 28th 2019

The FDA has approved the combination of ibrutinib and obinutuzumab for the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

Duvelisib Provides CLL Patients With a Later Line of Therapy

January 24th 2019

Ian W. Flinn, MD, PhD, discusses the potential impact of duvelisib on patients with chronic lymphocytic leukemia.

Dr. Seymour Discusses Rationale for MURANO Study in CLL

January 22nd 2019

John F. Seymour, MBBS, PhD, clinical hematologist, associate director of Clinical Research, Peter MacCallum Centre, director of the integrated Haematology Department of the Peter MacCallum Cancer Centre and the Royal Melbourne Hospital, discusses the rationale for the MURANO study in patients with chronic lymphocytic leukemia.

Dr. Arora on Novel Therapies in CLL

January 18th 2019

Shagun Arora, MD, assistant clinical professor at the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses novel therapies in the treatment of patients with chronic lymphocytic leukemia (CLL).

Dr. Hill on Resistance to BTK Inhibition in CLL

January 16th 2019

Brian T. Hill, MD, PhD, assistant professor, Hematology and Oncology, Cleveland Clinic, discusses resistance to BTK inhibition in chronic lymphocytic leukemia (CLL).

Targeting BCL-2 in Hematologic Malignancies

January 11th 2019

Over the past 2 decades, considerable efforts have focused on the development of therapies that can restore apoptosis in malignant cells.

BCL-2: Mechanisms and Prevalence

January 10th 2019

The understanding of the BCL2 oncogene and the BCL-2 protein family have motivated the current advancements in cancer therapeutics that target different members of apoptotic regulatory networks.

The Future of AML Therapy: Cause for Optimism

January 8th 2019

IDH Inhibitors in AML Therapy

January 8th 2019

BTK/BCL2 Inhibitors & Other Novel Agents in CLL Therapy

January 8th 2019

Treatment Options for Relapsed/Refractory AML

January 8th 2019

Treatment Options for Relapsed/Refractory CLL

January 8th 2019

Venetoclax-Based Regimens as First-Line Therapy in AML

January 8th 2019

Venetoclax-Based Regimens as First-Line Therapy in CLL

January 8th 2019

Glasdegib, Gilteritinib, and Quizartinib Against AML

January 8th 2019

Venetoclax for CLL After Progression on 1 Prior Therapy

January 8th 2019

Midostaurin Plus Chemotherapy for FLT3-Mutated AML Cases

January 8th 2019

Efficacy and Safety of Ibrutinib-Containing Regimens in CLL

January 8th 2019

Mutational Drivers of Acute Myeloid Leukemia

January 8th 2019